TABLE 2.

Intracellular lamivudine-TP pharmacokinetic parameters

Parametera	Lamivudine regimen		B/A ratio
	A (150 mg twice daily)	B (300 mg once daily)
AUC24,SS (pmol · h/106 cells)
n	55	54
GLS mean (95% CI)	85.38b (73.71, 98.89)	86.71b (74.38, 101.08)
GLS mean ratio (90% CI)			0.99 (0.88, 1.11)
Arithmetic mean ± SD	96.99 ± 46.88	99.58 ± 51.48
% CV	48	52
Median	95.51	92.39
Range	15.35-222.28	14.86-251.32
Cmax,ss (pmol/106 cells)
n	55	54
GLS mean (95% CI)	8.15b (6.99, 9.51)	7.74b (6.56, 9.14)
GLS mean ratio (90% CI)			0.93 (0.81, 1.07)
Arithmetic mean ± SD	9.45 ± 5.09	9.20 ± 5.55
% CV	54	60
Median	8.25	7.77
Range	1.81-24.77	1.86-25.47
C0,ss (pmol/108 cells)
n	54	53
GLS mean (95% CI)	1.84b (1.43, 2.38)	1.42b (1.10, 1.85)
GLS mean ratio (90% CI)			0.76 (0.58, 1.00)
Arithmetic mean ± SD	2.48 ± 1.72	2.11 ± 1.95
% CV	69	93
Median	2.11	1.61
Range	0-6.69	0.13-8.80
C24,SS (pmol/106 cells)
n	55	53
GLS mean (95% CI)	2.40b (1.79, 3.23)	1.97b (1.43, 2.72)
GLS mean ratio (90% CI)			0.82 (0.58, 1.14)
Arithmetic mean ± SD	3.17 ± 3.54	2.62 ± 3.25
% CV	112	124
Median	2.71	1.90
Range	0-17.08	0-17.56
Cave,ss (pmol/106 cells)
n	55	54
GLS mean (95% CI)	3.55b (3.07, 4.12)	3.61b (3.10, 4.21)
GLS mean ratio (90% CI)			0.99 (0.88, 1.11)
Arithmetic mean ± SD	4.04 ± 1.95	4.15 ± 2.15
% CV	48	52
Median	3.98	3.85
Range	0.64-9.26	0.62-10.47

^aAUC_24,ss, area under the intracellular lamivudine concentration-versus-time curve from 0 to 24 h after dosing at steady state; C_max,SS, maximum measured intracellular lamivudine concentration at steady state; C_0,ss, intracellular lamivudine concentration just prior to the next administered dose (steady-state trough concentration; C_24,ss, intracellular lamivudine concentration at 24 h after dosing at steady state; C_ave,ss, average intracellular lamivudine concentration over the dosing interval; t_max, time at which C_max occurred.

^bNumber is log-transformed.